Cervical Intraepithelial Neoplasia

1. Clinical Overview

Summary

Cervical intraepithelial neoplasia (CIN) is a premalignant condition characterized by dysplastic changes in the squamous epithelium of the uterine cervix. CIN represents a spectrum of histological abnormalities graded 1-3 based on the proportion of epithelial thickness occupied by dysplastic cells. Virtually all cases are caused by persistent infection with high-risk human papillomavirus (HPV), particularly genotypes 16 and 18, which together account for approximately 70% of cervical cancers worldwide. [1,2]

CIN is typically asymptomatic and detected through organized cervical screening programmes using HPV testing and/or cervical cytology. The introduction of HPV-based primary screening has significantly improved sensitivity for detecting high-grade lesions compared to cytology alone. Definitive diagnosis requires histological assessment of cervical biopsies obtained at colposcopy. [3]

The natural history of CIN is variable: low-grade lesions (CIN 1) frequently regress spontaneously, particularly in younger women, while high-grade lesions (CIN 2/3) have a significant risk of progression to invasive cervical cancer if untreated. Treatment, typically by excision using large loop excision of the transformation zone (LLETZ/LEEP), is highly effective with cure rates exceeding 90%. The implementation of HPV vaccination programmes has demonstrated dramatic reductions in CIN incidence in vaccinated populations, representing a paradigm shift in cervical cancer prevention. [4,5]

Key Anatomical Concepts

The Transformation Zone: The transformation zone (TZ) is the dynamic area of the cervix where columnar epithelium (endocervix) undergoes metaplasia to become squamous epithelium (ectocervix). This zone is the site of origin for virtually all cervical squamous neoplasia due to the vulnerability of actively dividing metaplastic cells to HPV infection and oncogenic transformation.

• Original Squamocolumnar Junction (SCJ): The junction between native squamous and columnar epithelium, determined in fetal life.
• New SCJ: The current position of the junction, which migrates toward the external os under estrogenic influence during puberty and pregnancy.
• Transformation Zone: The area between the original and new SCJ, containing metaplastic epithelium.
• Colposcopic Types:
  • "Type 1: Entirely ectocervical (visible in its entirety)"
  • "Type 2: Endocervical component (partially visible)"
  • "Type 3: Entirely within endocervical canal (not visible) - higher risk of missed lesions"

Why the Transformation Zone is Vulnerable:

• Active cell division during squamous metaplasia increases susceptibility to HPV integration
• Exposure to micro-abrasions during sexual intercourse facilitates HPV access to basal cells
• Immature metaplastic epithelium is more permissive to HPV infection
• The TZ is the most common site of HPV persistence and neoplastic change [6]

CIN Grading System

Note: The WHO now recommends the two-tier LSIL/HSIL classification system, but CIN 1/2/3 terminology remains widely used in clinical practice and examination settings. [7]

Clinical Pearls

"HPV Is the Necessary Cause": High-risk HPV (HR-HPV) is detected in > 99% of cervical cancers, making it the most attributable cause of any human malignancy. HPV types 16 and 18 together cause approximately 70% of cervical cancers, while types 31, 33, 45, 52, and 58 account for an additional 20%. Most HPV infections are transient, cleared by cell-mediated immunity within 12-24 months. It is persistence of HR-HPV infection beyond 2 years that predisposes to CIN development. [1,2]

"CIN 1 = Watch and Wait": CIN 1 is biologically distinct from CIN 2/3 and is considered a productive viral infection rather than a true precancer. Approximately 60% of CIN 1 lesions regress spontaneously within 2 years, with higher regression rates in younger women. Treatment is only indicated for persistent CIN 1 (> 2 years) or at patient request. Overtreatment of CIN 1 increases obstetric morbidity (preterm birth) without significant oncological benefit. [8,9]

"CIN 3 Is Carcinoma In Situ - The Critical Threshold": CIN 3 represents full-thickness dysplasia and is the obligate precursor to invasive squamous carcinoma. Without treatment, approximately 30% of CIN 3 lesions progress to invasive cancer over 30 years. Importantly, CIN 3 is a reversible lesion - even some cases of CIN 3 can regress spontaneously, particularly in young women. However, treatment is always recommended for CIN 3 due to the significant progression risk and inability to reliably predict which lesions will progress. [10]

"LLETZ Is Gold Standard Treatment": Large Loop Excision of the Transformation Zone (LLETZ), also known as LEEP (Loop Electrosurgical Excision Procedure), has revolutionized treatment of CIN since its introduction in 1989. It is simultaneously diagnostic (histological confirmation) and therapeutic (complete excision), can be performed under local anaesthesia as an outpatient procedure, and has success rates of 90-95% for CIN 2/3 with low complication rates. "See-and-treat" strategies at first colposcopy appointment are now standard practice for high-grade disease. [11,12]

"CGIN: The Hidden Danger": Cervical glandular intraepithelial neoplasia (CGIN), or adenocarcinoma in situ (AIS), is the glandular equivalent of CIN arising from endocervical columnar epithelium. Unlike CIN, CGIN can occur as "skip lesions" (multifocal, non-contiguous disease) within the endocervical canal, making complete excision challenging. Positive or uncertain margins after LLETZ/cone require repeat excision or hysterectomy. CGIN is associated with higher rates of HPV 18 (compared to squamous lesions) and requires more intensive follow-up. [13]

Why This Matters Clinically

Cervical screening programmes are among the most successful public health interventions, reducing cervical cancer incidence and mortality by over 80% in countries with organized screening. CIN is the paradigm of cancer prevention: a detectable, treatable precursor with a long natural history allowing intervention before malignant transformation. Understanding the HPV-CIN-cancer pathway, colposcopy assessment, and appropriate management of different grades of CIN is essential for all clinicians involved in women's health. The combination of HPV vaccination and screening has the potential to eliminate cervical cancer as a public health problem within a generation. [14,15]

---

2. Epidemiology

Incidence and Prevalence

CIN:

• Prevalence of abnormal cytology: 2-5% of women undergoing cervical screening have cytological abnormalities requiring further investigation
• CIN 1: Most common grade, affecting approximately 1-2% of screened women
• CIN 2/3 (High-grade): Combined prevalence approximately 0.3-0.5% of screened women
• Peak age for CIN: 25-35 years (reflecting peak HPV acquisition 10 years earlier)
• Age-specific patterns: CIN 1 more common in younger women (20s), CIN 2/3 relatively constant from 25-50 years

Cervical Cancer (when CIN is not detected/treated):

• Global incidence: 604,000 new cases and 342,000 deaths in 2020 (4th most common cancer in women)
• UK incidence: Approximately 3,200 new cases per year
• Australia incidence: Approximately 900 new cases per year (declining post-HPV vaccination)
• Age distribution: Bimodal peaks at 30-34 and 70-74 years

Trends:

• Declining CIN and cervical cancer rates in countries with organized screening programmes
• Dramatic reduction in HPV-related disease in HPV-vaccinated populations
• Shift from cytology to HPV-based primary screening improving detection of high-grade lesions [4,14,16]

Risk Factors

Essential Cause:

Cofactors Increasing Progression Risk:

Protective Factors:

---

3. Pathophysiology

HPV Biology and Cervical Carcinogenesis

HPV Structure and Genomics: Human papillomaviruses are small, non-enveloped, double-stranded DNA viruses with a circular genome of approximately 8,000 base pairs. Over 200 HPV genotypes are recognized, of which approximately 40 infect the anogenital tract. These are classified as:

• High-Risk (Oncogenic): Types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68
• Low-Risk (Non-Oncogenic): Types 6, 11, 40, 42, 43, 44 (associated with genital warts, low CIN grade)

The HPV genome encodes:

• Early genes (E1, E2, E4, E5, E6, E7): Regulate viral replication and host cell transformation
• Late genes (L1, L2): Encode viral capsid proteins (L1 is the basis of prophylactic HPV vaccines)
• Long Control Region (LCR): Regulates gene expression

The HPV-CIN Pathway: Step-by-Step Carcinogenesis

Step 1: Infection

• HPV infects basal keratinocytes of the cervical epithelium via micro-abrasions
• The transformation zone is most susceptible due to active metaplasia
• Virus maintains episomal (circular, extrachromosomal) form in basal cells
• E1 and E2 proteins drive low-level viral replication

Step 2: Productive Infection (CIN 1)

• In differentiated superficial cells, viral replication amplifies
• E4 protein disrupts cytokeratin network, causing koilocytosis (pathognomonic halo cells)
• Late genes express capsid proteins; virions are released as cells desquamate
• This is a productive (permissive) infection with minimal cellular transformation
• Robust cell-mediated immune response usually clears infection within 12-24 months

Step 3: Viral Persistence and Integration

• In 10-20% of women, HR-HPV persists beyond 24 months
• Persistence is the key risk factor for progression to high-grade CIN
• HPV DNA may integrate into host genome, disrupting E2 gene
• E2 normally represses E6 and E7 expression; its disruption leads to oncogene overexpression

Step 4: Oncogenic Transformation (CIN 2/3) The E6 and E7 oncoproteins of high-risk HPV types drive cellular transformation:

E6 Oncoprotein:

• Binds and degrades p53 tumor suppressor via ubiquitin-mediated proteolysis
• p53 normally induces cell cycle arrest and apoptosis in response to DNA damage
• Loss of p53 function: Genomic instability, escape from apoptosis

E7 Oncoprotein:

• Binds and inactivates retinoblastoma protein (pRb)
• pRb normally inhibits E2F transcription factors, preventing S-phase entry
• Release of E2F: Uncontrolled S-phase entry, continuous cell proliferation

Combined Effect:

• Dysregulated cell cycle with continued proliferation
• Impaired DNA repair and accumulating genetic mutations
• Immortalization of epithelial cells (overcome replicative senescence)
• Result: Full-thickness dysplasia (CIN 3)

Step 5: Invasion (If Untreated)

• Accumulation of additional genetic alterations (chromosomal instability, epigenetic changes)
• Disruption of basement membrane by protease activity
• Invasion of underlying stroma
• Timeline: 10-30 years from initial HPV infection to invasive cancer (longer than most epithelial cancers)
• Only a minority of persistent CIN 3 lesions progress to invasion [1,2,10,18]

Natural History: Regression, Persistence, Progression

Factors Favoring Regression:

• Younger age (less than 30 years)
• Low-grade histology (CIN 1)
• Non-16/18 HPV genotypes
• Smaller lesion size
• Robust immune response

Factors Favoring Progression:

• Older age (> 30 years)
• HPV 16 or 18 genotype
• Persistent HR-HPV infection
• High-grade histology (CIN 3)
• Large lesion size
• Immunosuppression
• Smoking [8,10,19]

Special Consideration: CGIN (Adenocarcinoma In Situ)

Cervical glandular intraepithelial neoplasia (CGIN/AIS) differs from squamous CIN:

CGIN is increasing in incidence relative to CIN, possibly due to preferential detection and treatment of squamous lesions. It accounts for approximately 20% of cervical carcinomas (adenocarcinoma). [13]

---

4. Clinical Presentation

Typical Presentation

CIN is asymptomatic - detection relies entirely on screening.

Symptoms Suggesting Invasive Cancer

[!CAUTION] Red Flags - Suspect Cervical Cancer, Not CIN:

• Post-coital bleeding (bleeding after intercourse)
• Intermenstrual bleeding
• Post-menopausal bleeding
• Persistent watery, blood-stained, or offensive vaginal discharge
• Visible cervical lesion on speculum examination
• Contact bleeding on examination
• Pelvic pain or dyspareunia (advanced disease)
• Renal failure from ureteric obstruction (advanced disease)

Important: Any woman with these symptoms should undergo urgent colposcopy and biopsy, regardless of recent screening results. A normal smear does NOT exclude invasive cancer.

Screening Terminology

Cytology-Based Reporting (UK):

The Bethesda System (International/USA):

Screening Pathways and Referral

UK NHS Cervical Screening Programme (HPV Primary Testing):

         HPV TEST RESULT
              ↓
    ┌─────────┴─────────┐
    │                   │
 HPV NEGATIVE        HPV POSITIVE
    ↓                   ↓
 Routine recall    CYTOLOGY TRIAGE
 (3-5 years)            ↓
              ┌─────────┴─────────┐
              │                   │
        CYTOLOGY NORMAL     CYTOLOGY ABNORMAL
              ↓                   ↓
        Repeat HPV test      COLPOSCOPY
        at 12 months              ↓
              ↓             Management based
    ┌─────────┴─────────┐   on colposcopy and
    │                   │   histology
 HPV NEGATIVE        HPV POSITIVE
    ↓                   ↓
 Return to          Repeat cytology
 routine recall     at 24 months
 (3 years)               ↓
                    ┌─────────┴─────────┐
                    │                   │
              HPV NEGATIVE        HPV POSITIVE
                    ↓                   ↓
              Routine recall      COLPOSCOPY

Referral Urgency:

---

5. Clinical Examination

Speculum Examination

Colposcopy: The Gold Standard

Colposcopy is the magnified examination of the cervix under bright illumination with application of chemical solutions to highlight abnormal areas. It is the essential investigation for any woman with abnormal screening results.

Equipment:

• Colposcope: Binocular microscope providing 6-40x magnification
• Green filter: Enhances visualization of blood vessels
• Acetic acid (3-5%): Causes acetowhite change in abnormal epithelium
• Lugol's iodine: Stains normal glycogen-containing epithelium brown

Acetic Acid Application (3-5%):

Mechanism: Acetic acid coagulates intracellular proteins. Dysplastic cells have high nuclear density and increased protein content, causing more intense whitening.

Vascular Patterns:

Lugol's Iodine (Schiller's Test):

Note: Lugol's iodine is useful for delineating lesion margins for biopsy/treatment but is non-specific.

Colposcopy Adequacy (Swede Score):

Inadequate colposcopy (Type 3 TZ) may require excisional biopsy for diagnosis rather than punch biopsy.

Colposcopy Documentation:

• Systematic documentation using diagrams or digital photography
• Record: TZ type, lesion location, acetowhite appearance, vascular patterns, lesion size (percentage of cervix involved)
• Swede Score or Reid Colposcopic Index for standardized grading [11,21]

Colposcopic-Histological Correlation

---

6. Investigations

Cervical Screening Tests

1. HPV Testing:

• Method: PCR or signal amplification to detect high-risk HPV DNA or mRNA
• Sensitivity: > 95% for CIN 2+ (more sensitive than cytology)
• Specificity: 85-90% (lower than cytology due to transient infections)
• Role: Primary screening test in UK, Australia, Netherlands, and increasing number of countries
• Interpretation:
  • "HPV-negative: Very low risk of CIN 2+ (less than 0.1% over 5 years); return to routine screening"
  • "HPV-positive: Risk depends on cytology; proceed to triage or colposcopy"

2. Liquid-Based Cytology (LBC):

• Method: Cells collected in liquid preservative; thin-layer preparation
• Sensitivity: 50-60% for CIN 2+ (lower than HPV testing)
• Specificity: 95-99% (higher than HPV testing)
• Role: Triage of HPV-positive women; direct screening in some countries
• Advantages over conventional smear: Fewer inadequate samples; reflex HPV testing from same sample

3. Dual Staining (p16/Ki-67):

• Emerging biomarker for triage of HPV-positive women
• p16 overexpression indicates E7 activity; Ki-67 indicates proliferation
• Co-expression in same cell suggests high-grade abnormality
• May improve specificity of triage [3,7,22]

Colposcopy and Biopsy

1. Punch Biopsy:

• Small tissue sample (2-3mm) taken from acetowhite areas
• Multiple biopsies from different areas if lesion heterogeneous
• Minimal morbidity; outpatient procedure
• Provides histological diagnosis (CIN grade)

2. Excisional Biopsy (LLETZ/Cone):

• Removes entire transformation zone for histological assessment
• Diagnostic and therapeutic
• Indicated for:
  • High-grade colposcopic impression ("see-and-treat")
  • Suspected CGIN (glandular abnormality)
  • Type 3 transformation zone (SCJ not visible)
  • Discordance between cytology and colposcopy/biopsy

3. Endocervical Curettage (ECC):

• Sampling of endocervical canal
• Used if Type 3 TZ or suspected glandular abnormality
• Helps detect disease extending into canal [11,12]

Histopathology Reporting

Key Elements of Report:

• CIN grade (1, 2, or 3 / LSIL or HSIL)
• Involvement of margins (if excision): Complete excision vs involved margins
• Depth of excision and specimen dimensions
• HPV-related features (koilocytosis)
• Glandular abnormality (CGIN/AIS if present)
• Any features of invasion

p16 Immunohistochemistry:

• Strong block-positive staining supports high-grade diagnosis
• Weak or patchy staining favors CIN 1/reactive changes
• Recommended for ambiguous CIN 2 cases (distinguishes true CIN 2 from mimics)

---

7. Management

Management Philosophy

The goal of CIN management is to prevent cervical cancer while minimizing overtreatment and its associated morbidity. Key principles:

1. Risk-Stratified Approach: Treatment intensity proportional to progression risk
2. Conservative Management for Low-Grade Disease: Most CIN 1 regresses spontaneously
3. Definitive Treatment for High-Grade Disease: CIN 2/3 requires treatment due to significant progression risk
4. Fertility Preservation: Minimize excision volume where oncologically safe
5. Test of Cure: HPV-based follow-up to confirm resolution

Management Algorithm

         HISTOLOGY-CONFIRMED CIN
                    ↓
    ┌───────────────┴───────────────┐
    │                               │
  CIN 1                         CIN 2/3
    ↓                               ↓
CONSERVATIVE             ┌──────────┴──────────┐
MANAGEMENT               │                      │
    ↓                 CIN 2 in             CIN 3 (any age)
Repeat HPV/cytology   women less than 30              CIN 2 in women > 30
at 12 months              ↓                      ↓
    ↓                 CONSIDER              TREATMENT
    │                 SURVEILLANCE          (LLETZ/Cone)
    │                 × 12-24 months            ↓
┌───┴───┐                 ↓              ┌──────┴──────┐
│       │          Regression? → Yes → Return to routine
HPV+/   HPV−       No ↓                        │
Abnormal Normal    TREATMENT               Histology:
↓       ↓         (LLETZ)                 Complete excision?
Colposcopy Return                              ↓
or treat  to routine                   ┌───────┴───────┐
         recall                        │               │
                                      YES             NO
                                       ↓               ↓
                                  Test of Cure    Further treatment
                                  (HPV at 6 months) or surveillance

1. Conservative Management (CIN 1)

Rationale: CIN 1 is a manifestation of productive HPV infection with high spontaneous regression rates. Treatment causes unnecessary morbidity without significant oncological benefit.

Protocol:

• Surveillance: Repeat cytology/HPV testing at 12 months
• Outcomes:
  • "If HPV-negative: Return to routine screening (3-5 years)"
  • "If HPV-positive with normal cytology: Repeat at 12 months; colposcopy if persistent at 24 months"
  • "If abnormal cytology: Colposcopy"
• Duration: Surveillance for up to 24 months
• Treatment Triggers:
  • Persistent CIN 1 at 24 months
  • Patient preference after counselling
  • Progression to CIN 2/3
  • Immunocompromised patient (lower threshold for treatment)

Counselling Points:

• Explain that CIN 1 is not cancer
• Most cases resolve without treatment
• Importance of attending follow-up appointments
• Smoking cessation advice (reduces HPV persistence)
• Safe sex advice (reduces re-infection) [8,9,23]

2. Treatment for CIN 2

Individualized Approach:

Surveillance Protocol for Young Women with CIN 2:

• Repeat colposcopy and cytology at 6-month intervals
• Duration: Up to 24 months
• Proceed to treatment if:
  • No regression by 24 months
  • Progression to CIN 3
  • Patient preference
  • Lost to follow-up concern

3. Excisional Treatment (LLETZ/LEEP)

Large Loop Excision of the Transformation Zone (LLETZ) / Loop Electrosurgical Excision Procedure (LEEP):

Indications:

• CIN 2/3 (all cases of CIN 3; CIN 2 if treatment chosen)
• Persistent CIN 1 (> 24 months)
• Discordance between cytology (high-grade) and biopsy (negative/CIN 1)
• Suspected CGIN/glandular abnormality
• Type 3 transformation zone (SCJ not visible)
• "See-and-treat" for high-grade colposcopic impression

Technique:

1. Setting: Outpatient colposcopy suite; local anaesthesia (lignocaine with adrenaline)
2. Anaesthesia: Infiltration of cervix at 12, 3, 6, and 9 o'clock positions
3. Visualization: Colposcopy to identify lesion margins
4. Excision: Wire loop with diathermy current passed across cervix to excise TZ; depth typically 7-10mm (larger for Type 2/3 TZ)
5. Haemostasis: Ball diathermy to excision bed; Monsel's solution if required
6. Specimen Handling: Orientation maintained; sent for histological assessment

"See-and-Treat":

• LLETZ performed at initial colposcopy when high-grade impression
• Avoids two visits; immediate resolution
• Acceptable for women with high-grade cytology and high-grade colposcopic impression
• Not appropriate if any possibility of pregnancy, diagnostic uncertainty, or very young women

Post-Procedure Advice:

• Watery vaginal discharge for 4-6 weeks (normal healing)
• Avoid tampons, sexual intercourse, and swimming for 4 weeks
• Mild cramping common; simple analgesia
• Seek medical attention for: Heavy bleeding, offensive discharge, fever

Complications:

4. Cone Biopsy (Cold-Knife Cone/Laser Cone)

Indications:

• CGIN/adenocarcinoma in situ (deeper excision needed)
• Suspicion of microinvasion
• Type 3 TZ with suspected high-grade disease
• Recurrent CIN after previous LLETZ

Technique:

• General or regional anaesthesia (operating theatre)
• Cold knife or laser excision of cone-shaped specimen
• Deeper excision (15-25mm depth)
• Greater tissue removal than LLETZ

Advantages: Better margins for CGIN; more tissue for histological assessment Disadvantages: Higher morbidity; greater obstetric risk [11,12,24]

5. Other Treatment Modalities

Note: Ablative methods provide no histological specimen and are now rarely used in high-resource settings where LLETZ is available.

6. Management of CGIN (Adenocarcinoma In Situ)

Key Differences from CIN Management:

1. Excision margins critical: Involved or uncertain margins require further treatment
2. Skip lesions possible: Clear margins do not guarantee complete excision
3. Higher risk of residual disease: 10-20% recurrence even with clear margins
4. Hysterectomy consideration: Recommended if family complete and margins uncertain/involved

Management Algorithm for CGIN:

           CGIN ON HISTOLOGY
                  ↓
         EXCISION MARGINS?
    ┌──────────┴──────────┐
    │                     │
 COMPLETE           INCOMPLETE/
 EXCISION           UNCERTAIN
    ↓                     ↓
Fertility wishes?    Fertility wishes?
    │                     │
┌───┴───┐           ┌─────┴─────┐
│       │           │           │
YES     NO          YES         NO
↓       ↓           ↓           ↓
Surveillance  Hysterectomy  Repeat     Hysterectomy
+ HPV TOC     (preferred)   excision   (strongly recommended)
                            then
                            surveillance

Follow-up for CGIN: Annual cytology/HPV for 10 years minimum (higher risk of late recurrence) [13,25]

7. Test of Cure

Protocol:

• HPV test (with cytology triage if positive) at 6 months post-treatment
• HPV-negative: Return to routine screening (3-5 years)
• HPV-positive:
  • "If cytology normal: Repeat HPV test at 12 months"
  • "If cytology abnormal: Colposcopy"
  • "If still HPV-positive at 12 months with normal cytology: Colposcopy"

Success Rates:

• HPV-negative at 6 months: 90-95%
• Residual/recurrent disease: 5-10% (higher with involved margins, larger lesions, CGIN)

Margin Status and Risk:

8. Management in Special Situations

Pregnancy:

• Colposcopy is safe in pregnancy
• Biopsy only if invasion suspected (bleeding risk)
• Treatment is deferred until after delivery (risk of haemorrhage, preterm labour)
• Repeat colposcopy at 6-8 weeks postpartum
• Many CIN lesions regress postpartum due to immune recovery
• Exception: Suspected invasive cancer requires MDT management

Immunocompromised Women:

• Higher rates of persistence, progression, and recurrence
• Lower threshold for treatment of CIN 1
• More intensive follow-up post-treatment
• Consider prophylactic vaccination (therapeutic effect unproven but safe)

Post-Menopausal Women:

• Type 3 TZ more common (atrophic cervix)
• May require estrogen treatment before colposcopy to improve TZ visibility
• LLETZ/cone may be needed for diagnosis (not just punch biopsy) [23,26]

---

8. Complications and Obstetric Implications

Treatment-Related Complications

Obstetric Implications of Excisional Treatment

Preterm Birth Risk: The relationship between cervical excision and preterm birth is well-established:

Mechanism: Loss of cervical stroma and structural integrity leading to:

• Shortened cervix
• Reduced tensile strength
• Impaired mucus barrier function

Clinical Implications:

• Counsel women about preterm birth risk before treatment
• Consider fertility-sparing approach in young women
• Document excision depth in medical records
• In subsequent pregnancy:
  • Transvaginal cervical length measurement at 16-24 weeks
  • Consider prophylactic cerclage if very short cervix (less than 25mm) or history of preterm birth
  • Serial cervical length monitoring

Balancing Oncological and Obstetric Risk:

• Risk of cervical cancer if CIN 2/3 untreated is substantial (30% over 30 years for CIN 3)
• Risk of preterm birth is increased but absolute risk remains low for most women
• Benefits of treatment generally outweigh risks
• Minimize excision volume while ensuring adequate margins [24,27]

---

9. Prevention: HPV Vaccination

HPV Vaccines

Landmark Evidence: Vaccine Efficacy

Falcaro et al. (2021) - Lancet: Real-world impact of HPV vaccination in England [4,5]

This landmark study demonstrated near-elimination of cervical cancer in women vaccinated before HPV exposure, validating the prophylactic vaccine strategy.

Vaccination Programmes

UK Programme:

• Routine vaccination at age 12-13 years (school Year 8)
• Gender-neutral programme (boys and girls) since 2019
• Single-dose schedule (2022 onwards) for those under 15
• Two doses 6-24 months apart for those 15+

Catch-Up Vaccination:

• Available up to age 25 in many countries
• Reduces but does not eliminate risk if already HPV-exposed
• Still beneficial as most women not infected with all vaccine-type HPVs [4,5,28]

---

10. Evidence and Guidelines

Key Guidelines

Landmark Studies

1. HPV Vaccination Impact - Falcaro et al. (2021)

• Publication: Lancet 2021;398:2084-2092
• Finding: 87% reduction in cervical cancer in women vaccinated at age 12-13
• Significance: First direct evidence of cancer prevention from HPV vaccination
• DOI: 10.1016/S0140-6736(21)02178-4 [4]

2. HPV Primary Screening - Ronco et al. (2014)

• Publication: Lancet 2014;383:524-532
• Finding: HPV testing 60-70% more sensitive than cytology for detecting CIN 2+
• Significance: Basis for transition to HPV-based primary screening
• DOI: 10.1016/S0140-6736(13)62218-7 [3]

3. Natural History of CIN - Ostor (1993)

• Publication: Int J Gynecol Pathol 1993;12:186-192
• Finding: Defined regression, persistence, and progression rates for CIN grades
• Significance: Foundation for risk-stratified management
• DOI: 10.1097/00004347-199304000-00018 [10]

4. LLETZ and Preterm Birth - Kyrgiou et al. (2017)

• Publication: BMJ 2017;357:j2372
• Finding: Meta-analysis confirming increased preterm birth risk after cervical excision
• Significance: Informs counselling about obstetric implications
• DOI: 10.1136/bmj.j2372 [27]

5. CIN 2 Regression - Tainio et al. (2018)

• Publication: Lancet Oncol 2018;19:645-656
• Finding: 60% of CIN 2 in women under 30 regresses within 24 months
• Significance: Supports active surveillance for CIN 2 in young women
• DOI: 10.1016/S1470-2045(18)30078-X [9]

---

11. Prognosis and Outcomes

Natural History Outcomes

Treatment Outcomes

Factors Affecting Prognosis

---

12. Patient and Layperson Explanation

What is CIN?

CIN (cervical intraepithelial neoplasia) means there are abnormal changes in the cells on the surface of your cervix (the neck of the womb). It is NOT cancer, but if left untreated over many years, some cases could develop into cervical cancer. This is why we detect and treat CIN - to prevent cancer from ever developing.

What Causes CIN?

CIN is caused by a very common virus called human papillomavirus (HPV). Almost all adults who have been sexually active will have had HPV at some point. For most people, the immune system clears the virus naturally within 1-2 years, and it never causes any problems. In some women, the virus persists and causes the cell changes we call CIN.

How Was It Found?

CIN is found through cervical screening (previously called a "smear test"). The screening test checks for HPV and/or abnormal cells. Because CIN doesn't cause any symptoms, screening is the only way to find it early.

What Do the Grades Mean?

• CIN 1 (Low-Grade): Mild cell changes. About 60% of these go away on their own without any treatment. We usually just monitor with repeat tests.
• CIN 2 (Moderate): More significant changes. Some go away on their own (especially in younger women), but treatment is usually recommended.
• CIN 3 (High-Grade): The most significant changes. These need treatment because they have a higher chance of developing into cancer if left for many years.

What is the Treatment?

The most common treatment is called LLETZ (Large Loop Excision of the Transformation Zone). A doctor uses a small wire loop to remove the area of abnormal cells from your cervix. It takes about 10 minutes and is done as an outpatient procedure under local anaesthetic (you're awake but the area is numbed).

What Happens After Treatment?

• You may have a watery or blood-stained discharge for up to 4-6 weeks - this is normal healing
• Avoid tampons, sexual intercourse, and swimming for 4 weeks
• You'll have a follow-up test (HPV test) at 6 months to make sure the treatment has worked
• Over 90% of women are cured after one treatment

Will It Affect Having Children?

Treatment for CIN slightly increases the risk of giving birth early (preterm birth) in future pregnancies. However, the risk is small, and leaving CIN untreated poses a much greater risk (cancer). If you've had treatment, tell your midwife when you become pregnant so they can monitor your cervix during pregnancy.

How Can I Prevent CIN?

• HPV Vaccination: The most effective prevention. It's offered to all teenagers and prevents the HPV types that cause most cervical cancers and CIN.
• Cervical Screening: Attend your screening appointments regularly. Screening can find changes early when they're easily treatable.
• Stop Smoking: Smoking makes it harder for your body to clear HPV and increases CIN risk.
• Safe Sex: Using condoms reduces (but doesn't eliminate) HPV transmission.

---

13. Examination Focus

High-Yield Exam Topics

Sample Viva Questions

Q1: A 28-year-old woman is referred with high-grade dyskaryosis on cervical screening. Describe your management.

Model Answer: "High-grade dyskaryosis indicates probable CIN 2 or 3. I would arrange urgent colposcopy within 2 weeks.

At colposcopy, I would:

1. Take a history, including last menstrual period (exclude pregnancy) and previous cervical history
2. Perform colposcopic examination with acetic acid application
3. Assess the transformation zone type and lesion characteristics (acetowhite intensity, margins, vascular patterns)
4. If the appearance is consistent with high-grade CIN and the transformation zone is fully visible (Type 1 or 2), I would offer 'see-and-treat' LLETZ under local anaesthesia

The LLETZ specimen would be sent for histology to confirm the grade and assess excision margins.

Post-procedure, I would advise avoiding tampons, intercourse, and swimming for 4 weeks, and explain the expected watery discharge.

I would arrange a test of cure with HPV testing at 6 months. If HPV-negative, she would return to routine screening. If HPV-positive, she would require further cytology and potentially repeat colposcopy."

Q2: What are the colposcopic features that distinguish high-grade from low-grade CIN?

Model Answer: "Colposcopic features suggesting high-grade CIN include:

Acetowhite Changes:

• Dense, opaque acetowhite epithelium (rather than faint, translucent)
• Rapid appearance of acetowhite change (within 60 seconds)
• Sharp, well-demarcated margins (rather than feathered edges)
• Internal borders within the lesion

Vascular Patterns:

• Coarse punctation (irregular, widely-spaced vessel dots)
• Coarse mosaic pattern (irregular tile pattern, variable tile size)
• These reflect abnormal stromal vessels pushed aside by expanding neoplastic epithelium

Other Features:

• Large lesion size (occupying > 50% of transformation zone)
• Extension into endocervical canal
• Contact bleeding on examination

Features suggesting possible invasion:

• Atypical vessels (irregular branching, corkscrew pattern)
• Ulceration or surface irregularity
• Friable tissue with spontaneous bleeding
• Raised, exophytic appearance"

Q3: Explain the molecular mechanisms by which HPV causes cervical neoplasia.

Model Answer: "High-risk HPV causes cervical neoplasia through the actions of two key oncoproteins, E6 and E7:

E6 Oncoprotein:

• E6 binds to p53 tumour suppressor protein
• Promotes ubiquitin-mediated degradation of p53
• p53 normally induces cell cycle arrest and apoptosis in response to DNA damage
• Loss of p53 function leads to: genomic instability, failure to repair DNA damage, and escape from apoptosis

E7 Oncoprotein:

• E7 binds to retinoblastoma protein (pRb)
• Inactivates pRb, releasing E2F transcription factors
• pRb normally prevents cells from entering S-phase
• Loss of pRb control leads to: uncontrolled S-phase entry and continuous cell proliferation

Integration:

• In persistent infection, HPV DNA may integrate into host chromosomes
• Integration disrupts the E2 gene, which normally represses E6/E7
• Loss of E2 leads to overexpression of E6/E7 oncoproteins
• Combined effect: dysregulated cell cycle, immortalization of epithelial cells, and accumulation of genetic mutations leading to CIN and eventually invasive cancer

The transformation zone is particularly vulnerable because actively dividing metaplastic cells are more susceptible to HPV integration and oncogenic transformation."

Q4: What are the key differences between CIN and CGIN? How does management differ?

Model Answer: "CIN and CGIN are both premalignant conditions of the cervix but differ in several important ways:

Management Differences:

1. Excision requirements: CGIN requires more extensive excision (cone biopsy rather than LLETZ) to ensure adequate margins

2. Margin assessment: In CGIN, clear margins do not guarantee complete excision due to skip lesions. Even with clear margins, there is 10-20% recurrence risk.

3. Follow-up: CGIN requires more intensive, longer follow-up (annual for 10 years minimum)

4. Hysterectomy threshold: Lower threshold for hysterectomy if:

   • Family complete
   • Margins involved or uncertain
   • Multiple positive margins
   • Patient preference for definitive treatment

5. CGIN coexisting with CIN: Common finding; treat the higher-grade/higher-risk lesion"

Common Exam Errors

---

14. References

Guidelines

1. NHS Cervical Screening Programme. Cervical Screening: Programme Overview. UK Health Security Agency. https://www.gov.uk/guidance/cervical-screening-programme-overview

2. British Society for Colposcopy and Cervical Pathology. Colposcopy and Programme Management Guidelines. 2020. https://www.bsccp.org.uk

Key Evidence

3. Ronco G, Dillner J, Elfstrom KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524-532. DOI: 10.1016/S0140-6736(13)62218-7 [PMID: 24499816]

4. Falcaro M, Castanon A, Ndlela B, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021;398(10316):2084-2092. DOI: 10.1016/S0140-6736(21)02178-4 [PMID: 34741816]

5. Lei J, Ploner A, Elfstrom KM, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383(14):1340-1348. DOI: 10.1056/NEJMoa1917338 [PMID: 32997908]

6. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. 2005;191(5):731-738. DOI: 10.1086/427557 [PMID: 15688287]

7. Darragh TM, Colgan TJ, Cox JT, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med. 2012;136(10):1266-1297. DOI: 10.5858/arpa.LGT200570 [PMID: 22742517]

8. Moscicki AB, Ma Y, Wibbelsman C, et al. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol. 2010;116(6):1373-1380. DOI: 10.1097/AOG.0b013e3181fe777f [PMID: 21099605]

9. Tainio K, Athanasiou A, Tikkinen KAO, et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. BMJ. 2018;360:k499. DOI: 10.1136/bmj.k499 [PMID: 29487049]

10. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993;12(2):186-192. DOI: 10.1097/00004347-199304000-00018 [PMID: 8463044]

11. Prendiville W, Cullimore J, Norman S. Large loop excision of the transformation zone (LLETZ). A new method of management for women with cervical intraepithelial neoplasia. Br J Obstet Gynaecol. 1989;96(9):1054-1060. DOI: 10.1111/j.1471-0528.1989.tb03380.x [PMID: 2804009]

12. Martin-Hirsch PP, Paraskevaidis E, Bryant A, et al. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev. 2013;(12):CD001318. DOI: 10.1002/14651858.CD001318.pub3 [PMID: 24302546]

13. Salani R, Puri I, Bristow RE. Adenocarcinoma in situ of the uterine cervix: a metaanalysis of 1278 patients evaluating the predictive value of conization margin status. Am J Obstet Gynecol. 2009;200(2):182.e1-5. DOI: 10.1016/j.ajog.2008.08.015 [PMID: 18822400]

14. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet. 2004;364(9430):249-256. DOI: 10.1016/S0140-6736(04)16674-9 [PMID: 15262102]

15. WHO. Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem. World Health Organization. 2020. https://www.who.int/publications/i/item/9789240014107

16. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-19. DOI: 10.1002/(SICI)1096-9896(199909)189:1less than 12::AID-PATH431> 3.0.CO;2-F [PMID: 10451482]

17. International Collaboration of Epidemiological Studies of Cervical Cancer. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer. 2006;118(6):1481-1495. DOI: 10.1002/ijc.21493 [PMID: 16206285]

18. Doorbar J, Quint W, Banks L, et al. The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30 Suppl 5:F55-70. DOI: 10.1016/j.vaccine.2012.06.083 [PMID: 23199966]

19. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338(7):423-428. DOI: 10.1056/NEJM199802123380703 [PMID: 9459645]

20. Kocken M, Uijterwaal MH, de Vries AL, et al. High-risk human papillomavirus testing versus cytology in predicting post-treatment disease in women treated for high-grade cervical disease: a systematic review and meta-analysis. Gynecol Oncol. 2012;125(2):500-507. DOI: 10.1016/j.ygyno.2012.01.015 [PMID: 22366409]

21. Kyrgiou M, Athanasiou A, Kalliala IEJ, et al. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. Cochrane Database Syst Rev. 2017;11(11):CD012847. DOI: 10.1002/14651858.CD012847 [PMID: 29095502]

22. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342-350. DOI: 10.1038/nrc798 [PMID: 12044010]

23. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30 Suppl 5:F88-99. DOI: 10.1016/j.vaccine.2012.06.095 [PMID: 23199969]

---

Last Reviewed: 2026-01-09 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and local guidelines.